Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242510 | 0.82 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL22072991 | 0.82 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL30242473 | 0.82 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL1486976 | 0.82 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL23971377 | 0.81 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL29744876 | 0.81 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL16300094 | 0.81 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL17049887 | 0.79 | PREP (0.42) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL8182192 | 0.79 | PREP (0.42) | PREPNR1H2USP2SMN1; SMN2MEN1 | |
| SCHEMBL18449799 | 0.77 | PREP (0.40) | PREPNR1H2USP2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751337-A | Preparation method of high-purity nilaparib intermediate | 南京唯创远医药科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2020053600-A1 | ENANTIOMERIC COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-03-19 | — | — | WO | disclosed |
| US-10464861-B2 | Asymmetric addition reactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-11-05 | — | — | US | disclosed |
| EP-3307698-B1 | ASYMMETRIC ADDITION REACTIONS | UNIV OXFORD INNOVATION LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-3307698-B1 | ASYMMETRIC ADDITION REACTIONS | UNIV OXFORD INNOVATION LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-20180334414-A1 | ASYMMETRIC ADDITION REACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| WO-2016198836-A1 | ASYMMETRIC ADDITION REACTIONS | ISIS INNOVATION LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464861-B2 | Asymmetric addition reactions | CSPP1, CCRL2, CBR3 | PREP 625/4885NR1H2 2537/4885USP2 1137/4885 |
| US-20180334414-A1 | ASYMMETRIC ADDITION REACTIONS | CSPP1, CCRL2, CBR3 | PREP 625/4885NR1H2 2537/4885USP2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.